Medical Marijuana for Glaucoma in Florida
Eye disease causing elevated intraocular pressure and progressive vision loss.
Medically reviewed by Bruce Stratt, MD
Board-Certified Physician · OMMU Certified · Boca Raton, FL
Overview
Glaucoma is a group of eye diseases that damage the optic nerve — responsible for carrying visual signals from the eye to the brain — typically due to elevated intraocular pressure (IOP). This pressure imbalance occurs when the aqueous humor (fluid in the front of the eye) either accumulates excessively or drains inadequately. Glaucoma is the second leading cause of blindness worldwide and often progresses silently without symptoms until significant, irreversible vision loss has occurred, earning it the nickname "the silent thief of sight."
There are two primary forms: primary open-angle glaucoma (the most common, causing gradual peripheral vision loss) and acute angle-closure glaucoma (less common but more urgent, causing sudden eye pain, nausea, blurred vision, and seeing halos around lights). Standard treatments focus on reducing IOP through medicated eye drops, laser therapy, or surgery. While these approaches are effective for many patients, some experience intolerable side effects or achieve insufficient IOP control despite maximal conventional therapy.
Florida explicitly lists glaucoma as a qualifying condition under Statute 381.986. Cannabis was among the earliest recognized therapeutic applications in ophthalmology — research dating to the 1970s first demonstrated marijuana's ability to lower intraocular pressure, and glaucoma was one of the original conditions that drove early medical cannabis legislation nationwide.
How Medical Cannabis May Help
The foundational study by Hepler and Frank (JAMA, 1971) first demonstrated that marijuana smoking reduced intraocular pressure by 25–30% in healthy subjects, with the effect lasting 3–4 hours. This landmark publication launched decades of research into cannabinoids and glaucoma. A subsequent study (Merritt et al., Ophthalmology, 1980) confirmed IOP reduction in glaucoma patients specifically, with effects appearing within 60–90 minutes of cannabis use. A more recent randomized, placebo-controlled crossover study (Tomida et al., Ophthalmology, 2006) tested sublingual THC and CBD in glaucoma patients. THC at 5 mg produced a statistically significant IOP reduction 2 hours after administration. Notably, CBD did not reduce IOP and at higher doses (40 mg) actually produced a transient IOP increase — an important finding that means glaucoma patients should specifically seek THC-containing formulations rather than CBD-only products. THC activates CB1 receptors in the ciliary body of the eye, reducing aqueous humor production, and may also increase aqueous outflow through the trabecular meshwork. While the duration of action per dose is shorter than pharmaceutical eye drops (3–4 hours vs. 24 hours), medical cannabis provides a valuable option for patients who cannot tolerate conventional IOP-lowering medications, experience inadequate IOP control despite maximal therapy, or need supplemental pressure reduction. Cannabis also addresses secondary symptoms such as eye pain, nausea, and the stress of living with a progressive visual condition. Dr. Stratt will evaluate whether medical marijuana would be a beneficial addition to your glaucoma management plan, working in coordination with your ophthalmologist.
Individual results vary. Consult with Dr. Stratt to understand how cannabis therapy may apply to your specific situation.
What to Bring to Your Appointment
Bring a valid Florida ID and ophthalmology records documenting glaucoma diagnosis, recent IOP measurements, current medication regimen, and any visual field test results.
Frequently Asked Questions
Related Articles
Patient Resources
Get Your Medical Marijuana Card for Glaucoma
Schedule your evaluation with Dr. Stratt. Same-day state registry submissions for qualifying patients.